NGNE
Neurogene Inc.
$21.08
0.09
(0.43%)
| Exchange: | |
| Market Cap: | 326.515M |
| Shares Outstanding: | 18.894M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Rachel L. McMinn | |||||
| Full Time Employees: | 107 | |||||
| Address: |
|
|||||
| Website: | https://www.neurogene.com |
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
